Top

Published in:

01-11-2010

Evidence-based initiation of dopaminergic therapy in Parkinson's disease

Author: Janis M. Miyasaki

Published in: Journal of Neurology | Special Issue 2/2010

Abstract

The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.

Adams RN, Murrill E, McCreery R, Blank L, Karolczak M (1972) 6-Hydroxydopamine a new oxidation mechanism. Eur J Pharmacol 17:287–292CrossRefPubMed

American Psychiatric Association (2000) Diagnostic and statistical manual of mental ‘disorders, fourth edition (DSM-IV-TR). American Psychiatric Publishing, Washington, DCCrossRef

Clement MV, Long LH, Ramalingam J, Halliwell B (2002) The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 81:414–421CrossRefPubMed

de Bie R, Miyasaki J, Lang AE, Fox SH (2007) Clinical practice regarding dopamine-agonist use and driving in Parkinson’s disease. Can J Neurol Sci 34:438–442PubMed

Du F, Qian ZM, Zhu L, Wu XM, Yung WH, Tsim TY, Ke Y (2009) l-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PloS ONE (Electronic Resource) 4(2):e4593CrossRef

Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. NEJM 351(24):2498–2508CrossRefPubMed

Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonis treatment and age at motor symptoms onset. J Psychopharmacol 21(5):501–506CrossRefPubMed

Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson's disease: is it the drugs or the disease? Neuorlogy 67(5):853–858CrossRef

Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 14:633–643PubMed

10.

Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian movement disorders group. JAMA 287:255–263CrossRef

11.

Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson’s disease research group of the United Kingdom (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71:474–480CrossRefPubMed

12.

Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS (2009) Nonmotor symptoms in de novo Parkinson's disease before and after dopaminergic treatment. J Neurol Sci 15(287):200–204CrossRef

13.

Kostic V, Przedborski S, Flaster MS, Stemic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41:202–205PubMed

14.

Marin C, Aguilar E, Mengod G, Cortes R, Obeso JA (2009) Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats. Eur J Neurosci 30:823–832CrossRefPubMed

15.

Marras C, Lang A, Krahn M, Tomlinson G, Naglie G (2004) Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22–28CrossRefPubMed

16.

Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes J (1997) Glia protect fetal midbrain dopamine neurons in culture from l-DOPA toxicity through multiple mechanisms. J Neural Transm 104:317–328CrossRefPubMed

17.

Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson’s disease—an evidence-based review. Neurology 58:11–17PubMed

18.

Montel S, Bonnet AM, Bungener C (2009) Quality of life inr elation to mood, coping strategies and dyskinesia in Parkinson’s disease. J Geriatr Psychiatry Neurol 22:95–102CrossRefPubMed

19.

Nair VD, Olanow CW, Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25–32CrossRefPubMed

20.

Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson’s disease. Ann N Y Acad Sci 786:217–233CrossRefPubMed

21.

Parkinson study group CALM cohort investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson's disease. Arch Neurol 66:563–570CrossRef

22.

Parkinson study group (2002) Pramipexole versus levodopa as initial treatment for Parkinson’s disease. JAMA 284:1931–1938CrossRef

23.

Parkinson study group (2000) Beta CIT-SPECT assessment of progression of Parkinson’s disease in subjects participating in the CALM-PD study. Neurology 54:A90

24.

Parkinson study group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287:1653–1661CrossRef

25.

Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness and dopamine agonists in Parkinson’s disease. Mov Disord 18:659–667CrossRefPubMed

26.

Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P, The Chinese Parkinson study group (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771CrossRefPubMed

27.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A 5-year study of dyskinesias in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. NEJM 342:1484–1491CrossRefPubMed

28.

Suzuki K, Miyamoto T, Miyamoto M, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H, Iwasaki YM, Iijima M, Hirata K (2008) Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson’s disease. J Neurol Sci 271:47–52CrossRefPubMed

29.

Tanaka M, Sotomatsu A, Kanai H, Hirai S (1991) Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 101:198–203CrossRefPubMed

30.

van Rooden SM, Visser M, Verbaan, Marinus J, van Hilten JJ (2009) Patterns of motor and non-motor features in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:846–850CrossRefPubMed

31.

Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in parkinson disease. Neurology 67:1254–1257CrossRefPubMed

32.

Webster DD (1969) Quantitative measurements of l-dopa therapy in Parkinson’s disease. Trans Am Neurol Assoc 94:348–350PubMed

33.

Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J, Wunderlich GR, Lang AE (2008) Mov Disord 23(S1)Poster

Title: Evidence-based initiation of dopaminergic therapy in Parkinson's disease
Author: Janis M. Miyasaki
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Journal of Neurology / Issue Special Issue 2/2010
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-010-5718-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evidence-based initiation of dopaminergic therapy in Parkinson's disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 2/2010

The clinical spectrum of levodopa-induced motor complications

Soluble and controlled-release preparations of levodopa: do we really need them?

Has drug therapy changed the natural history of Parkinson’s disease?

Continuous dopaminergic delivery in Parkinson’s disease

Levodopa: back to the future

The role of the long-duration response to levodopa in Parkinson’s disease